Studies on new QIAGEN solutions for NGS are presented at ASHG as QIAseq portfolio and user base expands significantly.
Hilden, Germany, and Germantown, Maryland, Oct. 11, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of a breakthrough technology enabling faster, simpler library preparation for RNA sequencing. A key element of this portfolio is the QIAseq FastSelect RNA Removal Kit which provides a novel solution for scientists to target RNA types that are irrelevant to their research and remove them from RNA-seq libraries for next-generation sequencing (NGS). The global market size for library preparation kits for RNA-seq is believed to be about $400 million.
In addition to a highly competitive and differentiated line of RNA-seq solutions, several other QIAGEN solutions for accurate, efficient NGS will be showcased at ASHG 2018, the conference of the American Society of Human Genetics from October 16-20 in San Diego. In addition, more than 15 studies relying upon QIAseq solutions, the GeneReader NGS System and other QIAGEN Sample to Insight products will be presented in ASHG 2018 scientific sessions, demonstrating the unique positioning of QIAGEN in this rapidly growing market of next generation sequencing.
“The QIAseq FastSelect RNA Removal Kit allows rapid selective removal of RNA classes from any sample, even the most difficult FFPE samples, enabling researchers to attain high quality, reproducible RNA sequencing results while at the same time minimizing time requirements and cost. The QIAseq Fastselect RNA kit can accomplish in one simple workflow step what current RNA sequencing library preparation solutions achieve in over 30 steps. By using a range of proprietary, novel technologies, the QIAseq FastSelect RNA Removal kit therefore radically simplifies and speeds up RNA removal. Off-the-shelf options include rRNA or globin mRNA removal, while custom RNA removal solutions for selected transcripts can be designed by QIAGEN.” said Dr. Thomas Schweins, Senior Vice President of QIAGEN’s Life Sciences Business Area. “QIAGEN has built a global leadership position in universal solutions for RNA sequencing, and the introduction of QIAseq FastSelect for use on any NGS platform addresses a critical bottleneck for researchers and contributes to QIAGEN’s significant opportunities in the very large market of RNA sequencing library preparation solutions. We are pleased to offer this valuable addition to our Sample to Insight portfolio for next-generation sequencing laboratories in the life sciences.”
Ribonucleic acid, or RNA, controls many genetic processes at the cellular level and is a growing subject for NGS research, but the process of library preparation often is slowed by some RNA types that are abundant in cells but irrelevant to the specific research. With QIAseq FastSelect Kits, scientists can exclude specific targets such as ribosomal RNA (rRNA) or globin for human, mouse or rat samples, or use QIAGEN’s custom design service to enable removal of specific RNAs for additional species and targets. A simple one-step, 20-minute incubation with the FastSelect RNA removal reagent during RNA fragmentation and cDNA synthesis effectively reduces the targeted RNA for removal to 1% or less.
QIAseq FastSelect RNA Removal Kits complement QIAGEN’s expanding portfolio of RNA-seq solutions, including the QIAseq UPX 3’ Transcriptome/Targeted RNAseq Kits for ultraplex RNA-seq NGS libraries from single cells or low RNA-input samples; QIAseq miRNA Library Kit for small RNA sequencing with a gel-free workflow; QIAseq Stranded Library Kits that allow stranded RNA sequencing with an innovative and fast workflow (less than 5 hours); and QIAseq Immune Repertoire kits for T-cell receptor clonotyping.
QIAGEN’s QIAseq portfolio focuses on providing precise NGS data by incorporation of unique molecular indexes (UMIs) and advanced data analysis for alignment and interpretation. For more information on QIAGEN NGS technologies, application focus and the new FastSelect kits, please visit www.qiagen.com/
A few key abstracts and times for presentation of QIAGEN-related studies at ASHG 2018:
- Scientists with QIAGEN Bioinformatics compared results of automated variant classification using QIAGEN Clinical Insight (QCI) software with ENIGMA expert panel assessments of BRCA1 and BRCA2 variants in 6,154 cases, demonstrating a 99.6% rate of concordance with respect to clinical actionability. (PgmNr 969: “Automated classification of BRCA1 and BRCA2 variants shows near perfect concordance with ENIGMA expert panel assessments,” 2:00-3:00 p.m. Friday Oct. 19.)
- QIAGEN researchers conducted a systematic evaluation of errors caused by library construction and sequencing methodology to identify and minimize physical and computational errors in NGS libraries, allowing reliable calling of mutations at levels far below the typical 1% limit. (PgmNr 3052/T: “Advances in targeted NGS: Towards robust ultralow mutation detection in small and large DNA panels,” 3:00-4:00 p.m. Thursday Oct. 18.)
- QIAGEN researchers describe a high-throughput 3’ RNA-seq library prep methodology called QIAseq Ultraplex to analyze the heterogeneity of an ostensibly uniform population of cancer cells, identifying unique signatures of genes that drive cellular clustering. (PgmNr 923, “High-throughput, reduction transcriptomics, using ultraplex RNA sequencing,” 2:00-3:00 p.m. Friday Oct. 19.)
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of June 30, 2018, QIAGEN employed approximately 4,800 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).